Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT03615846
Other study ID # VFN-CSS-19-0008
Secondary ID
Status Active, not recruiting
Phase
First received
Last updated
Start date February 15, 2021
Est. completion date October 30, 2022

Study information

Verified date September 2021
Source Accriva Diagnostics
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

This is a multi-center convenience sample prospective study comparing the results of the Verify Now® Aspirin Test and PRUTest® Platelet Reactivity Tests with the Japan investigational reagents to reagents registered in Japan in the expected population receiving aspirin (ASA) and the P2Y12 inhibitor clopidogrel.


Description:

- The Primary Objectives of this study are to compare the results of: - The VerifyNow Aspirin Test with AA, an investigational reagent as defined in Japan, against LTA with AA investigational reagent as defined in Japan (study reference reagent), in subjects receiving DAPT (ASA and clopidogrel or subjects taking no platelet inhibitors including ASA; - The VerifyNow Aspirin Test with AA, an investigational reagent as defined in Japan, against LTA with collagen (study reference reagent), o In subjects receiving DAPT (ASA and clopidogrel) or in subjects taking no platelet inhibitors including ASA - The VerifyNow PRUTest with ADP, an investigational reagent as defined in Japan, and PGE1, against LTA with ADP, an approved reagent in Japan (study reference reagent) and PGE1, and - The VerifyNow PRUTest with ADP (an investigational reagent as defined in Japan) and PGE1 against LTA with ADP reagent approved in Japan (study reference reagent) with no PGE1, o in up to 75 subjects receiving DAPT (ASA and clopidogrel) and in up to 55 subjects taking no platelet inhibitors (total up to 130 subjects).


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 147
Est. completion date October 30, 2022
Est. primary completion date October 30, 2021
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Males and females 18 years of age or older. - Subjects regularly taking ASA and clopidogrel, for a minimum of 4 days prior to enrollment, or subjects taking no platelet inhibitors including ASA. - Willing to participate and able to understand the study, including their rights and any risks associated with their participation, and sign an informed consent. - Able and willing to donate a blood sample of 15mL. • Exclusion Criteria - Enrolled in any other study that involves an investigational drug and/or device. - Smoked within one hour before blood draw. - Had caffeine within 2 hours before blood draw. - Had meals with high fat content within 8 hours before blood draw. - A platelet count below 92,000/µL, or above 502,000/µL for VerifyNow Aspirin Test.* - A platelet count below 119,000/µL, or above 502,00/µL for VerifyNow PRUTest.* - A hematocrit level below 29%, or above 56% for VerifyNow Aspirin Test.* - A hematocrit level below 33%, or above 52% for VerifyNow PRUTest.* - Within the past 48 hours, exposure to any of the following drugs: - Antiplatelet/glycoprotein inhibitors [eptifibatide, tirofiban] - Any antiplatelet drug except clopidogrel and ASA [e.g. ticagrelor, prasugrel]

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
United States Accriva Study Site Baltimore Maryland
United States Accriva Study Site Jacksonville Florida

Sponsors (1)

Lead Sponsor Collaborator
Accriva Diagnostics

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary VerifyNow® PRUTest Correlation of AggRAM Light Transmittance Aggregometry (LTA) compared to VerifyNow PRUTest 1 day
Primary VerifyNow® Aspirin Test Correlation of AggRAM Light Transmittance Aggregometry (LTA) compared to VerifyNow Aspirin Test 1 day
Primary Naive Correlation of AggRAM Light Transmittance Aggregometry (LTA) compared to VerifyNow Aspirin Test and VerifyNow PRUTest 1 day
See also
  Status Clinical Trial Phase
Recruiting NCT06030596 - SPECT Myocardial Blood Flow Quantification for Diagnosis of Ischemic Heart Disease Determined by Fraction Flow Reserve
Completed NCT04080700 - Korean Prospective Registry for Evaluating the Safety and Efficacy of Distal Radial Approach (KODRA)
Recruiting NCT03810599 - Patient-reported Outcomes in the Bergen Early Cardiac Rehabilitation Study N/A
Recruiting NCT06002932 - Comparison of PROVISIONal 1-stent Strategy With DEB Versus Planned 2-stent Strategy in Coronary Bifurcation Lesions. N/A
Not yet recruiting NCT06032572 - Evaluation of the Safety and Effectiveness of the VRS100 System in PCI (ESSENCE) N/A
Recruiting NCT04242134 - Drug-coating Balloon Angioplasties for True Coronary Bifurcation Lesions N/A
Recruiting NCT05308719 - Nasal Oxygen Therapy After Cardiac Surgery N/A
Completed NCT04556994 - Phase 1 Cardiac Rehabilitation With and Without Lower Limb Paddling Effects in Post CABG Patients. N/A
Recruiting NCT05846893 - Drug-Coated Balloon vs. Drug-Eluting Stent for Clinical Outcomes in Patients With Large Coronary Artery Disease N/A
Recruiting NCT06027788 - CTSN Embolic Protection Trial N/A
Recruiting NCT05023629 - STunning After Balloon Occlusion N/A
Completed NCT04941560 - Assessing the Association Between Multi-dimension Facial Characteristics and Coronary Artery Diseases
Completed NCT04006288 - Switching From DAPT to Dual Pathway Inhibition With Low-dose Rivaroxaban in Adjunct to Aspirin in Patients With Coronary Artery Disease Phase 4
Completed NCT01860274 - Meshed Vein Graft Patency Trial - VEST N/A
Recruiting NCT06174090 - The Effect of Video Education on Pain, Anxiety and Knowledge Levels of Coronary Bypass Graft Surgery Patients N/A
Terminated NCT03959072 - Cardiac Cath Lab Staff Radiation Exposure
Completed NCT03968809 - Role of Cardioflux in Predicting Coronary Artery Disease (CAD) Outcomes
Recruiting NCT04566497 - Assessment of Adverse Outcome in Asymptomatic Patients With Prior Coronary Revascularization Who Have a Systematic Stress Testing Strategy Or a Non-testing Strategy During Long-term Follow-up. N/A
Recruiting NCT05065073 - Iso-Osmolar vs. Low-Osmolar Contrast Agents for Optical Coherence Tomography Phase 4
Completed NCT05096442 - Compare the Safety and Efficacy of Genoss® DCB and SeQuent® Please NEO in Korean Patients With Coronary De Novo Lesions N/A